2011-12-21 20:11:14 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Rochester Medical Corporation and produced a Rating Update Report, rating the company's attractiveness to long-term investors.

Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering Rochester Medical Corporation (ROCM). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Rochester Medical Corporation investor.

Report Summary: Rochester Medical Corporation is a low quality company with a positive outlook. Rochester Medical Corporation has strong business growth and is run by passable management. The trend in Rochester Medical Corporation fair value exchange rate against its closest rated-competitor, Derma Sciences, Inc., has been depreciating over the past 2 weeks. When compared to its closest competitor, Rochester Medical Corporation shows similar overvaluation and is equally likely to underperform the market.

The 3-page report breaks down the Total StockMark into its three

components – business, management and price, performing an in-depth analysis of Rochester Medical Corporation for long-term investors.

The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
www.sadifanalytics.com/stockmarks/company-ru-125-ROCM

About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.